Curis, Inc. (CRIS)Healthcare | Biotechnology | Lexington, United States | NasdaqCM
0.60 USD
-0.02
(-3.274%) ⇩
(Oct. 14, 2026, 4 p.m.
EDT)
After hours: 0.60 +0.00 (0.834%) ⇧ (Oct. 14, 2026, 4:47 p.m. EDT) |
Hot Take ↕ | Oct. 10, 2026, 9:02 a.m. EDT
The immediate outlook is severely bearish as the stock has lost nearly 99.5% of its value over the last nine years, with the most recent annual performance showing another significant decline. While the current price sits near its five-year low, the technical picture remains precarious; the stock is trading well below both its 50-day and 200-day moving averages, indicating persistent downward pressure rather than a stabilization. The statistical forecast model predicts further downside over the next 45 days, though its very low confidence suggests this prediction is driven by extreme price volatility rather than a reliable trend. Fundamentally, the company is in deep distress, reporting negative operating margins, burning through cash, and carrying a forward P/E that implies negative earnings expectations. The balance sheet is fragile with a current ratio below 0.5 and substantial debt relative to equity. Despite a wide gap between the current price and the mean analyst target, the lack of analyst coverage and the deteriorating operational metrics suggest the market has already priced in a catastrophic failure of the business model. There is no dividend to provide income, and the capital structure appears unsustainable without a successful turnaround in the pipeline, which currently faces execution risks. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.491644 |
| AutoARIMA | 0.808653 |
| AutoETS | 0.808654 |
| MSTL | 0.819865 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 26% |
| H-stat | 14.95 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.030 |
| Excess Kurtosis | -1.41 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 22.236 |
| Revenue per Share | 2.213 |
| Market Cap | 1,454,561 |
| Trailing P/E | 0.45 |
| Forward P/E | -0.10 |
| Beta | 3.10 |
| Website | https://www.curis.com |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.9799342 |
| Address1 | Building C |
| Address2 | Suite 500 128 Spring Street |
| All Time High | 54,500.0 |
| All Time Low | 0.59 |
| Ask | 1.29 |
| Ask Size | 1 |
| Average Daily Volume10 Day | 197,090 |
| Average Daily Volume3 Month | 202,415 |
| Average Volume | 202,415 |
| Average Volume10Days | 197,090 |
| Beta | 3.1 |
| Bid | 1.46 |
| Bid Size | 3 |
| Book Value | 2.409 |
| City | Lexington |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 0.5998 |
| Current Ratio | 0.492 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 0.6199 |
| Day Low | 0.58 |
| Debt To Equity | 22.236 |
| Display Name | Curis |
| Dividend Date | 1,527,638,400 |
| Dividend Yield | 0.0 |
| Earnings Call Timestamp End | 1,778,617,800 |
| Earnings Call Timestamp Start | 1,778,617,800 |
| Earnings Timestamp End | 1,793,908,800 |
| Earnings Timestamp Start | 1,793,908,800 |
| Ebitda | -35,869,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | 0.076 |
| Enterprise To Revenue | -0.636 |
| Enterprise Value | -2,743,707 |
| Eps Current Year | -23.77667 |
| Eps Forward | -6.01333 |
| Eps Trailing Twelve Months | 1.32 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 1.5204 |
| Fifty Day Average Change | -0.92060006 |
| Fifty Day Average Change Percent | -0.60549855 |
| Fifty Two Week Change Percent | -97.99342 |
| Fifty Two Week High | 33.6 |
| Fifty Two Week High Change | -33.0002 |
| Fifty Two Week High Change Percent | -0.9821488 |
| Fifty Two Week Low | 0.58 |
| Fifty Two Week Low Change | 0.019800007 |
| Fifty Two Week Low Change Percent | 0.034137946 |
| Fifty Two Week Range | 0.58 - 33.6 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 965,136,600,000 |
| Float Shares | 1,836,613 |
| Forward Eps | -6.01333 |
| Forward P E | -0.099745065 |
| Free Cashflow | -15,766,000 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 20 |
| Fullday Change | -0.0153000355 |
| Fullday Change Percent | -2.4673495 |
| Fullday Price | 0.6048 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Gross Profits | -21,339,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.06455 |
| Held Percent Institutions | 0.29007998 |
| Implied Shares Outstanding | 2,425,078 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,783,296,000 |
| Last Split Factor | 1:20 |
| Long Business Summary | Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small-molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single-arm expansion trial in patients with relapsed/refractory primary central nervous system lymphoma. The company's pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; CA-170, an oral, small-molecule antagonist designated as CA-170 that selectively targets PD-L1 and VISTA; and CA-327, an oral, small molecule, TIM3/PD-L1, which is a molecule antagonist of PD-L1 and TIM3. It has collaboration agreements with Genentech Inc., or Genentech and F. Hoffmann-La Roche Ltd, or Roche, for the commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway antagonist for the treatment of advanced basal cell carcinoma, or BCC; Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology; and also licensed three programs under the Aurigene collaboration, including emavusertib. Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts. |
| Long Name | Curis, Inc. |
| Market | us_market |
| Market Cap | 1,454,561 |
| Market State | POST |
| Max Age | 86,400 |
| Message Board Id | finmb_27159 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -21,153,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 2,308,431 |
| Number Of Analyst Opinions | 3 |
| Open | 0.619 |
| Operating Cashflow | -30,587,000 |
| Operating Margins | -8.33403 |
| Payout Ratio | 0.0 |
| Phone | 617 503 6500 |
| Post Market Change | 0.004999995 |
| Post Market Change Percent | 0.8336104 |
| Post Market Price | 0.6048 |
| Post Market Time | 1,792,010,830 |
| Previous Close | 0.6201 |
| Price Eps Current Year | -0.025226409 |
| Price Hint | 4 |
| Price To Book | 0.24898298 |
| Price To Sales Trailing12 Months | 0.33717224 |
| Profit Margins | 0.0 |
| Quick Ratio | 0.371 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.02030003 |
| Regular Market Change Percent | -3.2736704 |
| Regular Market Day High | 0.6199 |
| Regular Market Day Low | 0.58 |
| Regular Market Day Range | 0.58 - 0.6199 |
| Regular Market Open | 0.619 |
| Regular Market Previous Close | 0.6201 |
| Regular Market Price | 0.5998 |
| Regular Market Time | 1,792,008,001 |
| Regular Market Volume | 122,858 |
| Return On Assets | -0.93231004 |
| Revenue Per Share | 2.213 |
| Sand P52 Week Change | 0.17004645 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 2,425,078 |
| Shares Percent Shares Out | 0.074 |
| Shares Short | 179,462 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 168,213 |
| Short Name | Curis, Inc. |
| Short Percent Of Float | 0.0746 |
| Short Ratio | 1.2 |
| Source Interval | 15 |
| State | MA |
| Symbol | CRIS |
| Target High Price | 65.0 |
| Target Low Price | 20.0 |
| Target Mean Price | 42.66667 |
| Target Median Price | 43.0 |
| Total Cash | 5,073,000 |
| Total Cash Per Share | 2.427 |
| Total Debt | 1,044,000 |
| Total Revenue | 4,314,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | 1.32 |
| Trailing P E | 0.45439392 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 10.24425 |
| Two Hundred Day Average Change | -9.64445 |
| Two Hundred Day Average Change Percent | -0.94145006 |
| Type Disp | Equity |
| Volume | 122,858 |
| Website | https://www.curis.com |
| Zip | 2,421 |